+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 90Years
All Genders
ID07309094

Effects of GLP-1 Receptor Agonists on Fat Tissue and Kidney Health in Adults with Chronic Kidney Disease and Type 2 Diabetes

Led by Cardenal Herrera University · Updated on 2025-12-30

250

Participants Needed

1

Research Sites

74 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the relationship between adiposopathy, a malfunction of fat tissue, and chronic kidney disease CKD, a condition where kidney function progressively worsens. This study focuses on patients with CKD stages 1 to 4 who also have type 2 diabetes, cardiovascular diseases, or obesity. The study aims to understand how treatment with glucagon-like peptide-1 receptor agonists GLP-1RA, such as semaglutide and tirzepatide, affects adiposopathy and related kidney and heart risks. CKD progression is linked to increased cardiovascular risk, especially in severe stages requiring dialysis, and adiposopathy may worsen this risk through inflammation. Participants will be in one of several groups receiving different treatments weekly subcutaneous injections of GLP-1RA semaglutide or tirzepatide with dose escalation, daily oral SGLT2 inhibitors, or other standard CKD care medications not involving GLP-1RA or SGLT2 inhibitors. The treatment phase lasts 16 months, during which changes in adipose tissue thickness around organs and kidney function will be monitored using ultrasound and blood tests. Throughout the 16 months, participants will undergo evaluations including ultrasound measurements of various fat tissue areas, blood tests for markers like leptin and adiponectin, and urine tests for kidney injury indicators. Researchers will track changes in fat tissue distribution and kidney function to assess treatment effects. Participants will provide informed consent and be monitored periodically to measure the study outcomes and safety.

CONDITIONS

Brief Title

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

Research Team

A

Ana Checa-Ros, MD, PhD

L

Luis D'Marco, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here